Cite
HARVARD Citation
Dupoiron, D. et al. (2017). A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR. European journal of pain. pp. 1528-1537. [Online].